We conducted research based on life sciences transactions that closed between 2010 and 2017 to learn whether M&A contributes to shareholder value.
Choose your deal strategy wisely
2018 M&A Firepower Report: Life sciences deals and data
Life sciences deal intentions remain above trend
MDR and IVDR: reshaping Europe’s medtech industry
Looking beyond China to create a global IVD company
Medtech innovation for the aging world
The operating room of the future
Building value through creative deal structures
Investing in China for the long term
Finding sustainability in biotechnology, pharmaceutical and medical technology
Amplified business decisions are the new norm thanks to rapid changes. From new market entrants and regulatory reform to expiring patents and the growing challenge of chronic diseases, leaders in the life sciences community must explore a new course to address the changing climate for health care — one driven by patients and focused on health outcomes.
Our Global Life Sciences Center brings together a worldwide team of professionals to help you achieve your potential.
We cover key issues in these areas:
Jon Junyoung Huh
Tel: +82 2 3787 6378
Connect with us
Stay connected with us through social media, email alerts or webcasts. Or download our EY Insights app for mobile devices.
1-2 November 2012
Philadelphia, Pennsylvania (US)
Presented by EY and Real Endpoints
Join us at this premier event which brings together senior executives from leading product (pharma, medtech, biotech) companies along with payers, providers and policymakers to discuss the key issues that will set the product reimbursement agenda over the next few years.